<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="731030" id="root" date="1997-07-15" xml:lang="en">
<title>NORWAY: Nycomed in deal with U.S. drugs firm.</title>
<headline>Nycomed in deal with U.S. drugs firm.</headline>
<dateline>OSLO 1997-07-15</dateline>
<text>
<p>Norwegian drugs company Nycomed ASA said on Tuesday it entered into a licensing agreement with Targeted Diagnostics and Therapeutics (TDT) of the United States to develop TDT's proprietary technology for both imaging and therapeutic applications to colorectal cancer.  </p>
<p>Under the agreement, Nycomed has obtained exclusive worldwide rights to develop and market products in return for an up-front payment, licence fees and milestone payments potentially totalling $21 million, Nycomed said in a statement.</p>
<p>TDT will receive royalties on marketed products arising from the agreement.</p>
<p>Nycomed and TDT will collaborate on the development of imaging agents for staging of colorectal cancer as well as therapeutic agents for the treatment of metastatic disease of colorectal origin.</p>
<p>Both indications address significant currently unmet medical needs, Nycomed said.</p>
<p>According to the American Cancer Society, an estimated 130,000 new cases of colorectal cancer will be diagnosed in 1997, and nearly 55,000 people will die from the disease.</p>
<p>Surpassing both breast cancer and prostate cancer in mortality, colorectal cancer is second only to lung cancer in terms of numbers of deaths in the United States. Only 7 percent of all patients diagnosed with distant metastasis from colorectal cancer survive for more than five years.</p>
<p>Nycomed on July 1 announced plans to merge with Britain's Amersham International Plc.</p>
<p>--Tanya Pang, Oslo newsroom, +47 22 42 50 41</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="NORW">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-15"/>
  </code>
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-15"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25000">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-15"/>
  </code>
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-15"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C23">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-15"/>
  </code>
  <code code="C33">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-15"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-15"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-07-15"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-07-15"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="OSLO"/>
<dc element="dc.creator.location.country.name" value="NORWAY"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
